ABSTRACT
Background Rheumatoid arthritis (RA) is an autoimmune disease that usually causes synovial inflammation, cartilage and bone deformity, and is associated with the production of rheumatoid factor (RF) and anti-citrullinated protein antibody (1-3). The ocular, cardiovascular and other systemic complications of this disease are of significant concern (4-6). In particular, the eye is susceptible to inflammation or autoimmune disorders and shows ocular manifestations that may be early clinical symptoms of systemic vasculitis in some rheumatic disease cases (7-8). This study used optical coherence tomography angiography (OCTA) to evaluate retinal and conjunctival microvascular alterations in RA patients.
Methods Twelve patients (24 eyes) with a history of at least 5 years of rheumatoid arthritis (RA) were identified from their medical records and compared with 12 normal controls (24 eyes). The microvasculature of each eye was measured quantitatively using OCTA images. The images were manually segmented into representations of two physiologic layers: the superficial retinal layer (SRL) and the deep retinal layer (DRL). The microvascular (SMIR, DMIR), macrovascular (SMAR, DMAR) and total microvascular (STMI, DTMI) density were quantified and calculated in each layer. Simultaneously, macular retinal area was segmented into different regions based on the hemisphere segmentation (SR, SL, IL, and IR), early treatment of diabetic retinopathy study (ETDRS; R, S, L, and I) and central wheel division methods (C1-C6). Microvasculature measurements were used to compare microvascular densities between RA and normal controls and to explore the correlation between microvascular alteration and disease.
Results Compared with the control group, superficial and deep retinal layer microvascular density was decreased in the RA group. The STMI (p<0.0001), DTMI (p<0.0001), SMIR (p<0.0001), and DMIR (p<0.0001), were lower in RA than in controls, while the SMAR (p=0.207), and DMAR (p=0.828), density was statistically similar between groups. A significant difference was found in both superficial and deep layers in S (p<0.0001), SL (p<0.0001 and p<0.0004 respectively), SR (p<0.0001 and p=0.008 respectively), IL (p<0.0001) and C1 (p<0.0001 and p<0.004 respectively), C2 (p<0.0001 and p=0.0002 respectively), C4 (p=0.02 and p=0.007 respectively) regions, and additionally in the L (p<0.0001), I (p=0.004), C3 (p<0.0001) and C5 (p=0.002), regions in the superficial layer. Similarly, the temporal conjunctival vessel density was found to be lower in RA patients than in controls (t=2.030; P=0.048). In RA group, a statistically positive correlation was indicated between conjunctival microvascular and STMI densities (correlation coefficient 0.712, p=0.02).
Conclusion RA is complicated by several severe ocular symptoms and causes superficial and deep microvascular density alteration. This finding could precede diagnosis of the underlying RA and may be a useful factor in early diagnosis and the avoidance of long-term sequelae in systemic rheumatic diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Key Research Foundation of Jiangxi Province (No: 20203BBG73059, 20181BBG70004)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the First Affiliated Hospital of Nanchang University gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Statement: This was not an industry supported study. The authors report no conflicts of interest in this work.
Funding Disclosure: Key Research Foundation of Jiangxi Province (No: 20203BBG73059, 20181BBG70004); Excellent Talents Development Project of jiangxi Province (20192BCBL23020); Natural Science Foundation of jiangxi Province(20181BAB205034); Grassroots Health Appropriate Technology “Spark Promotion Plan” Project of Jiangxi Province (No:20188003); Health Development Planning Commission Science Foundation of Jiangxi Province (No: 20201032); Health Development Planning Commission Science TCM Foundation of Jiangxi Province (No: 2018A060)
Ethical Statement: All research methods were conformed to the ethical requirements of the First Affiliated Hospital of Nanchang University and were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The method and purpose of the study were informed and consented to all subjects prior to participation.
Data Availability
All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript